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Background. The arterial pharmacokinetics of ketamine and norketamine enantiomers after 
racemic ketamine or S-ketamine i.v. administration were evaluated in seven gelding ponies in a 
crossover study (2-month interval).
Methods. Anaesthesia was induced with isoflurane in oxygen via a face-mask and then main­
tained at each pony’s individual MAC. Racemic ketamine (2.2 mg kg ') or S-ketamine 
(I. I mgkg ') was injected in the right jugular vein. Blood samples were collected from the 
right carotid artery before and at 1,2, 4, 8, 16, 32, 64, and 128 min after ketamine adminis­
tration. Ketamine and norketamine enantiomer plasma concentrations were determined by 
capillary electrophoresis. Individual R-ketamine and S-ketamine concentration vs time curves 
were analysed by non-linear least square regression two-compartment model analysis using 
PCNonlin. Plasma disposition curves for R-norketamine and S-norketamine were described by 
estimating AUC, Cmax, and Tmax. Pulse rate (PR), respiratory rate (Rf), tidal volume (VT), 
minute volume ventilation (VE), end-tidal partial pressure of carbon dioxide (Peco,), and mean 
arterial blood pressure (MAP) were also evaluated.
Results. The pharmacokinetic parameters of S- and R-ketamine administered in the racemic 
mixture or S-ketamine administered separately did not differ significantly. Statistically significant 
higher AUC and Cmax were found for S-norketamine compared with R-norketamine in the 
racemic group. Overall, Rf, VE, Peco,, and MAP were significantly higher in the racemic group, 
whereas PR was higher in the S-ketamine group.
Conclusions. Norketamine enantiomers showed different pharmacokinetic profiles after 
single i.v. administration of racemic ketamine in ponies anaesthetised with isoflurane in oxygen 
(I MAC). Cardiopulmonary variables require further investigation.
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The rational use of ketamine, alone or in combination 
with volatile anaesthetics, relies on the knowledge of its 
disposition within the body, so that dose recommen­
dations can be established and adjusted according to the 
desired blood or plasma drug levels. Although the dispo­
sition of ketamine is well documented in horses,1 1 only 
one study reports the plasma levels of ketamine and 
norketamine enantiomers obtained after racemic (R-/S-) 
ketamine i.v. administration for anaesthesia induction in 
this species.5 This study showed higher plasma levels of 
S-norketamine than R-norketamine, suggesting that 
A'-de methylation might be highly enantioselective in 
horses. The potential for discrimination between enantio­
mers at different stages of drug metabolism is therefore 
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important and highlights the need for stereospecific drug 
assays.6
In humans and mice, the S-enantiomer has been proven 
advantageous, reaching an identical depth of anaesthesia 
with only half of the necessary racemic dose.7-9 
Differences in the metabolism of the ketamine enantio­
mers after R-/S-ketamine administration when compared 
with the sole S-ketamine administration might partially 
explain the faster recovery of the psychomotor function 
observed when S-ketamine is given alone.912
As a prelude to studying ketamine infusions in horses, 
the main goal of this study was to determine the pharma­
cokinetic profile of ketamine enantiomers after a single 
i.v. bolus of either R-/S-ketamine or S-ketamine in 
healthy ponies under isoflurane anaesthesia.
Materials and methods
Study design and animals
The experiments were performed with permission of the 
committee for animal experimentation, Bern, Switzerland. 
The experimental trial was designed as a randomized pro­
spective 2-month interval cross-over study. Seven exper­
imental, 4 year-old, Shetland pony geldings, mean weight 
122 kg (sd 16 kg), were included in this study. The ponies 
were administered first R-/S-ketamine (RS-k) and after 
2 months of wash-out interval, S-ketamine (S-k). They 
were conventionally housed as a group at the equine clinic 
of the Vetsuisse-Faculty (Bern, Switzerland). The animals 
had their right carotid artery surgically elevated to allow 
easy access by percutaneous puncture about 2 yr before 
this experiment and were judged healthy on the basis of 
physical examination, complete blood count and biochem­
istry profile. On the day before the experiment, ponies 
were housed in a separate box to allow withholding of 
food for 24 h. Access to water was granted until 1 h prior 
to the study.
Anaesthesia and instrumentation
The whole animal experimental phase was conducted in a 
padded recovery stall to both induce anaesthesia and 
allow for a safe anaesthetic recovery. A broad rope to 
restrain horses was placed around the ponies' pectoralis 
region, then passed around their hind quarters below their 
quadriceps and anchored to itself over the left side of their 
chest. After protective bandaging of the extremities, an 
additional rope was placed around every metacarpus/ 
metatarsus. By pulling and stretching the ropes gently, the 
ponies were smoothly placed in right lateral recumbency 
and restrained in that position until anaesthesia induction 
was achieved. Ponies were trained to be restrained with 
this technique from prior studies.13 Anaesthesia was then 
induced with isoflurane in oxygen (O2) via a hermetically 
closed face mask connected to a small-animal anaesthesia 
circle system (Roche Electronic Respirator 3100, 
F. Hoffmann-La Roche, Basel, Switzerland). The vapori­
zer was first set to 1% and isoflurane delivery started via 
the face mask (O2 flow: 6 litres min-1) and gradual incre­
ments of 0.5% were made over 5 min until the ponies 
reached an appropriate anaesthetic plane for endotracheal 
intubation (muscle relaxation, eyeball rotation, reduced pal­
pebral reflex, absence of swallowing reflex). Subsequently, 
a 14 mm ID cuffed rubber-silicone tube was placed into 
their tracheas and connected to the breathing system. 
Ponies were let to breathe spontaneously throughout the 
whole procedure. In the event of apnoea longer than 30 s, 
intermittent positive pressure ventilation (IPPV) was 
applied by manually squeezing the reservoir bag of the 
breathing system twice per minute until spontaneous venti­
lation was restored. Anaesthesia was maintained with iso­
flurane in O2 throughout the whole experiment, at each 
pony's predetermined individual minimum alveolar con­
centration (iMAC). The iMAC for each pony [mean 0.97% 
(sd 0.17%)] was determined in a previous study.13
The skin over the right jugular vein and the left carotid 
artery was clipped and surgically prepared for percutaneous 
placement of intravascular catheters. The right jugular vein 
was catheterized with a 13-gauge catheter (Intranule PP, 
Vygon, Ecouen, France), and Ringer's lactate solution 
10 ml kg-1 h-1 (RLS, Laboratorium Bichsel Baar, 
Switzerland) was delivered intravenously throughout the 
procedure with the aid of two volumetric infusion pumps 
(Vet/IV 2.2 Heska, Ballerup, Denmark). The left carotid 
artery was catheterized using a 20G/1.10x45 mm arterial 
catheter (B-D Arterial Cannula with FloSwitch, Ohmeda, 
Swindon, UK). Later on, the jugular port served for test 
drug administration and the arterial port served for blood 
sampling and invasive blood pressure monitoring. To facili­
tate test drug administration or blood collection, three-way 
stopcock valves were attached to the hubs of the venous 
and arterial catheters between the RLS line and the invasive 
blood pressure line, respectively.
Anaesthesia monitoring and physiological 
data collection
A lead II electrocardiogram was displayed and haemo­
globin oxygen saturation (Spo) was determined with a 
pulse oximeter infrared probe placed on the tongue, which 
also calculated the pulse rate (PR). Inspired and expired 
O2 concentrations, end-expired isoflurane concentrations 
(Fe'jso). capnogram and end-tidal carbon dioxide partial 
pressure (Pi/o), tidal volume (VT), and minute volume 
ventilation (VE) were obtained from a calibrated pitot tube 
flow sensor and side-stream gas sampler probe (D-lite 
Patient Spirometry TM, Datex-Ohmeda, Helsinki, Finland) 
inserted between the endotracheal tube and the Y-piece of 
the breathing system. Respiratory rate (Ry) was calculated 
from the capnogram. Mean arterial pressure (MAP) was 
determined directly with a calibrated pressure transducer 
(Angiokard, Medizintechnik GmbH & Co. KG, Friedeburg, 
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Germany) from the catheter placed in the carotid artery. 
The zero level in the transducer was set at the presumed 
level of the heart base (point of shoulder). In addition, the 
difference of the pharyngeo-oesophageal temperature 
(87' ) between the initial value measured after endotracheal 
intubation and the final value measured at the end of the 
procedures was recorded. A portable anaesthesia monitor 
(Datex S-5 portable anaesthesia monitor, Datex-Ohmeda, 
Helsinki, Finland) continuously displayed the aforemen­
tioned data. The monitor was calibrated with a stan­
dardized calibration gas (DOT-34 NRC/375M1014, 
Datex-Ohmeda, Helsinki, Finland) prior to each exper­
iment according to the manufacturers' instructions. A 
laptop computer connected to the monitor served to record 
every 5 min the displayed data from 5 min before the test 
drug administration (baseline data) and throughout the 
sampling time. In addition, the need for IPPV was also 
manually recorded. After complete recovery from anaes­
thesia, animals were returned to their boxes.
Drug administration and sample collection
Ponies were left to stabilize end-tidal isoflurane concen­
trations to their individual isoflurane MAC for about 
20 min. A single i.v. dose of R-/S-ketamine (RS-k) 
2.2 mg kg-1 or S-ketamine (S-k) 1.1 mg kg-1 were admi­
nistered intravenously. Five millilitres of arterial blood 
were collected manually over 5 s into heparinized tubes 
from the carotid artery catheter immediately before and at 
1, 2, 4, 8, 16, 32, 64, 128 min after test drug injection. To 
avoid contamination with the arterial flushing solution, 
5 ml of blood was collected and discharged before every 
sampling event. After the samples were obtained, the 
arterial catheter was flushed with 10 ml of physiologic 
saline solution. Immediately after collection, the samples 
were placed on ice until centrifugation was performed 
(maximum: 45 min) and plasma was frozen at — 80cC 
until the assay was performed.
Ketamine and norketamine enantiomer analysis
The plasma samples were analysed by enantioselective 
capillary electrophoresis (CE) according to the technique 
described by Theurillat and colleagues,14 and plasma con­
centrations for R-ketamine, S-ketamine, R-norketamine, 
and S-norketamine were obtained. Briefly, this technique 
is based on liquid-liquid extraction of ketamine and nor­
ketamine at alkaline pH from 1 ml plasma followed by 
analysis of the reconstituted extract by CE in the presence 
of a pH 2.5 Tris-phosphate buffer containing highly sul­
fated p-cyclodextrin 10 mg ml-1 (Sigma Aldrich Chemie, 
Schnelldorf, Germany) as chiral selector. Analyses were 
performed on the P/ACE MDQ Capillary Electrophoresis 
Analyzer (Beckman Coulter, Fullerton, CA, USA) using a 
50 p,m ID fused-silica capillary of 28 cm effective length, 
an applied voltage of 20 kV and a cartridge temperature 
of 30cC. The detection wavelength was 195 nm. The limit 
of detection for all enantiomers was 0.01p,gml_1 and 
intraday and interday precisions (n=5) were <8% and 
<14%, respectively.
Ph a rmcicoki neti c ana lysis
R-ketamine and S-ketamine concentration vs time curves 
were analysed for each individual by non-linear least 
square regression two-compartment model analysis using 
PCNonlin (SCI Software, Lexington, USA). Plasma con­
centration obtained after i.v. administration was fitted to a 
polyexponential equation:
c(i! £>< 1
i
where C(f) (jig ml-1) is the plasma concentration at time /; 
T, (jig ml-1) is the coefficient of the zth term, and X., (per 
hour) is its exponent. Initial estimates were determined 
using the residual method15 and refitted by non-linear 
regression analysis. The number of exponents needed were 
determined by applying the Schwartz16 and Akaike cri­
teria.17 Most pharmacokinetic parameters were calculated 
using classic equations associated with compartmental 
analysis. Distribution and elimination half-lives (i^alpha 
and ij^beta, respectively) were calculated as L/2 
alpha=0.693/X.1 and /1/2beta=0.693/X,2- Area under the 
plasma concentration-time curve (AUC(o-M)) and mean 
residence time (MRT, measure of drug elimination 
expressed as the average time a drug molecule remains in 
the body after i.v. injection) were calculated by the trape­
zoidal rule with extrapolation to infinity. The extrapolated 
area was estimated as AUC(c co)=Ciast/X.2- where Ciast is 
the last measured concentration. Body clearance (C1B) was 
determined as ClB=dose/AUC(o-K>) and the steady-state 
volume of distribution (Vjdiss))) was calculated as 
V(d(ss))=ClBxMRT. Plasma disposition curves for 
R-norketamine and S-norketamine were described by esti­
mating AUC, Cmax, and Tmax.
Statistical methods
The NCSS 2004 (Kaysville, UT, USA) and the SigmaStat 
3.1 (Point Richmond, CA, USA) software packages were 
used to perform the statistical evaluation. All data were 
analysed for normal distribution with the Martinez-Iglewicz 
test. The significance of difference between groups for 87', 
ketamine, and norketamine enantiomers plasma levels and 
the estimated pharmacokinetic parameters was assessed with 
the Wilcoxon signed rank test or, when applicable, the 
Student's paired /-test. Each animal served as its own match. 
For PR, MAP, F’e'co,, Rf. and VE, a statistical comparison 
was made between SR-k and S-k treatment groups before 
and after test drug administration using an analysis of 
variance test and for VT using a two-way analysis on ranks 
Friedman test. For all tests, overall P<0.05 was considered 
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the minimum level of statistical significance. Parametric data 
are presented as mean (sd) and non-parametric data are 
presented as median and range.
Results
Anaesthesia
The overall induction, maintenance, and recovery from the 
anaesthetic episodes were uneventful. In one pony, the 
administration of the S-ketamine and the RLS infusions 
were performed via a 16-gauge catheter placed in the right 
cephalic vein because of obstruction of the left jugular 
vein catheter. Differences between treatment groups in 87' 
were not statistically significant [RS-k: 0.6 (0.4)cC; S-k: 
0.9 (0.6)°C],
Cardiopulmonary data
There were no statistically significant differences in the 
cardiopulmonary variables between groups during the 
baseline measurements. Trends for PR are presented in 
Figure 1. Ponies in the RS-k treatment group had signifi­
cantly lower (P<0.001) overall PR compared with the S-k 
treatment group (Fig. 1). Trends for MAP are presented in 
Figure 2. Overall MAP values where higher (P=0.006) in 
the RS-k when compared with the S-k group. Trends for 
Pe'co,, Ve- and Rf are presented in Figure 3. Ponies in the 
S-k treatment group had a significantly lower (P<0.001) 
Pt.' co2 compared with the RS-k treatment group (Fig. 3a). 
The VE was significantly higher (P<0.001) in the RS-k 
treatment group than in the S-k treatment group (Fig. 3b). 
Overall Revalues were higher (P<0.001) in the RS-k treat­
ment group than the S-k treatment group (Fig. 3c). 
Immediately after both test drug administrations, three of 
seven ponies in each group developed apnoea longer than 
30 s. After applying IPPV for 1-2 min all of them restored 
to spontaneous respiration. Differences in VT were not stat­
istically significant between treatment groups (RS-k group, 
median: 1.04 litre, range: 0.24-2.61 litre; S-k group, 
median: 0.99 litre, range: 0.05-3.06 litre). VT decreased
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Fig 2 Mean and sd of MAP plotted over time after R-/S-ketamine and 
S-ketamine administration to seven ponies anaesthetized with isoflurane 
in oxygen. The arrow marks the time of drug injection.
in both groups after test drug administration and restored 
to baseline values at 10 min. Mean Spo, for the entire 
anaesthetic episode was 99 (0.9)% in the RS-k treatment 
group and 98.8 (0.4)% in the S-k treatment group.
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Fig 3 Mean and sd of Pe'cOj (a)> Ve (b)> and R/ (c) plotted over time 
after R-/S-ketamine and S-ketamine administration to seven ponies 
anaesthetized with isoflurane in oxygen. The arrow marks the time of 
drug injection.
Fig 1 Mean and sd of PR plotted over time after R-/S-ketamine and 
S-ketamine administration to seven ponies anaesthetized with isoflurane 
in oxygen. The arrow marks the time of drug injection.
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Plasma concentrations of ketamine and 
norkefamine enantiomers
A total of 126 plasma samples (RS-k=63, S-k=63) were 
analysed by CE and used for the concentration-time data 
evaluation. R-ketamine and R-norketamine were not 
detected after administration of S-ketamine. Trends for 
ketamine and norketamine plasma concentrations are pre­
sented in Figures 4 and 5. S-ketamine plasma concen­
trations were statistically significantly lower (P=0.03) in 
the S-k treatment group than in the RS-k treatment group 
at 2 min (Figs 4a and 5a). At the same time point, 
S-ketamine plasma concentrations were statistically signifi­
cantly lower (P=0.005) when compared with the 
R-ketamine plasma concentrations in the RS-k treatment 
group (Fig. 4a). No other significant differences were 
determined. Plasma concentrations for S-norketamine were 
statistically significantly higher than plasma concentrations 
of R-norketamine in the RS-k group at 2 (P=0.005), 8 
(P=0.007), 16 (P=0.01), 32 (P=0.005), 64 (P=0.008), 
and 128 (P=0.03) min. No statistical difference was noted 
at 1 (P=0.297) and 4 (P=0.147) min. The plasma concen­
trations of the S-norketamine in the S-k group were 
similar to its homologous enantiomer in the RS-k group 
(P>0.05 for all time points. Figs 4b and 5b).
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Fig 5 Mean (sd) plasma concentrations of (a) S-ketamine and (b) 
S-norketamine after S-ketamine administration to seven ponies 
anaesthetized with isoflurane in oxygen. **P<0.05 between treatment 
groups (comparison with data of Fig. 4a).
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Fig 4 Mean and sd of plasma concentrations of (a) S-ketamine and 
R-ketamine and (b) S-norketamine and R-norketamine after R-/ 
S-ketamine administration to seven ponies anaesthetized with isoflurane 
in oxygen. *P<0.05 within treatment group. **P<0.05 between the two 
treatment groups (comparison with data of Fig. 5a).
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The pharmacokinetics for all ketamine enantiomers could 
be well described with a two-compartment model. No sig­
nificant differences in the pharmacokinetic variables 
between and within treatment groups could be detected for 
the ketamine enantiomers. The AUC and Cmax of 
R-norketamine were found to be significantly smaller 
(P=0.002 and P=0.009, respectively) than those of 
S-norketamine in the RS-k treatment group. No other sig­
nificant differences could be determined. Table 1 summar­
izes the results of the population analysis for all 
compounds.
Discussion
In the present study, the pharmacokinetic parameters of 
R- and S-ketamine after single i.v. injection of the race­
mate or the single S-enantiomer in ponies under isoflurane 
anaesthesia, did not significantly differ. The statistically 
significant differences found for the S-ketamine plasma 
concentrations 2 min after administration of either R-/S- 
or S-ketamine had no significant impact on the calculated 
pharmacokinetic variables. However, the statistically sig­
nificant differences found in the plasma disposition of S- 
and R-norketamine after administration of the racemate, 
mirrored by their calculated pharmacokinetic parameters, 
suggest that in ponies anaesthetized with 1 iMAC isoflur­
ane, the metabolism of racemic ketamine is highly
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Table 1 Mean (so) of pharmacokinetic parameters of arterial plasma S- and 
R-ketamine obtained from ponies (n=7) anaesthetized with isoflurane in 
oxygen after i.v, R-/S-ketamine (2,2 mg kg-1) or S-ketamine (1,1 mg kg-1) 
administration, *P<0,05 between enantiomers within the R-/S-ketamine 
treatment group. A, distributive exponential phase; B, terminal exponential 
phase; Alpha, hybrid rate constant of biphasic i.v. disposition curve 
(distribution phase); Beta, hybrid rate constant of biphasic i.v. disposition 
curve (elimination phase); K10, first-order elimination rate constant; KI2 and 
K21, first-order transfer rates between central and peripheral compartments; 
Cmax, maximum observed concentration value; Tmax, time point at which Cmax 
occurs
S-ketamine R-/S-ketamine
S-ketamine R-ketamine
A (p-gml ') 9.7 (14) 5.6 (2) 5.4 (1.6)
B i|mg ml ' i 0.7 (0.6) 0.4 (0.1) 0.5 (0.3)
Alpha (min \) 0.7 (0.5) 0.4 (0.0S) 0.4 (0.1)
Beta (min-1) 0.05 (0.05) 0.03 (0.01) 0.03 (0.01)
AUC (|xg min ml-1) 29.1 (18.1) 27.1 (6.34) 26.S (5.3)
ti^alpha (min) 1.4 (0.S) 1.6 (0.3) 1.7 (0.3)
i!/2beta (min) 26 (22.5) 23.6 (S.l) 24.2 (7.4)
K10 (mm ) 0.3 (0.2) 0.2 (0.05) 0.2 (0.05)
KI2 linin') 0.3 (0.2) 0.1 (0.05) 0.2 (0.1)
K21 (rum ') 0.1 (0.1) 0.06 (0.02) 0.07 (0.04)
Vc (litre kg ' ) 0.2 (0.1) 0.2 (0.06) 0.2 (0.1)
C1b (litre kg-1 min-1) 0.05 (0.02) 0.04 (0.01) 0.04 (0.01)
MRT (min) 24.6 (24.1) 1S.9 (6.2) 19.1 (5.7)
kdiss» (litre kg-1) 0.9 (0.S) 0.S (0.3) 0.S (0.3)
S-norketamine S-norketamine R-norketamine
AUC (p,g min ml-1) 14.S (0.5) 17.S (6.4)* 10.4 (3)*
()j.g ml j 0.4S (0.2) 0.5 (0.0S)* 0.4 (0.06)*
(min) 3.6 (2.3) 7.1 (4.5) 4.3 (l.S)
stereoselective. In both treatment groups, the arterial 
plasma concentrations of ketamine enantiomers followed a 
biexponential decline, with a rapid initial distribution 
phase being followed by a slower elimination phase. This 
profile was analogous to those previously published 
for humans,11 dogs,18 and cross-bred horses.5 Similar to 
humans and most other species,1 2 15 111 18 21 high variabi­
lity among individuals was observed in the plasma con­
centrations of ketamine and norketamine. Former studies on 
the pharmacokinetics of S-/R-ketamine in horses reported 
data analysed from venous samples.15 In isoflurane anaes­
thetized ponies, large differences (up to 50%) were found 
between arterial and venous pharmacokinetics of ketamine 
isomers caused by both, distribution and elimination pro­
cesses.22 In situations in which potent short-acting drugs are 
used, such as anaesthetics, these differences can be of con­
siderable importance.23 Because the drug concentrations at 
the target organ are probably more closely related to arterial 
than to venous concentration, the controlling parameters 
should be based on arterial rather than venous data.10 24 The 
present study is the first investigating the arterial 
stereoselective pharmacokinetic profile of S-/R-ketamine 
compared with S-ketamine in an equine species.
The iMAC is the midpoint of two end-tidal anaesthetic 
concentrations that just permit or just prevent gross purpose­
ful movement after applying a supramaximal stimulation 
in a single anaesthetized individual.25 Individual MAC 
values are normally averaged to obtain the MAC in a 
group of subjects. The use of each pony iMAC, instead of 
the MAC of the group, aimed to have a comparable degree 
of immobility among test animals. I.V. R-/S-ketamine at a 
dose of 2.2 mg kg-1 is well documented to induce anaes­
thesia in sedated horses.2 4 Such doses, however, are seldom 
administered in clinical practice to horses already receiv­
ing 1 MAC of isoflurane. This dose was chosen delibera­
tely to create a basis for further studies on constant rate 
infusion of ketamine in isoflurane-anaesthetized horses. 
As a racemate has equal proportions of each enantiomer, 
a dose of 1.1 mg kg-1 of S-ketamine was chosen to 
compare the profiles of the S-enantiomer in both treatment 
groups.
Previous investigations in rats21 and dogs26 anaesthe­
tized with halogenated agents showed alterations in organ 
perfusion, which in turn slowed down uptake, distribution, 
and redistribution of ketamine. Thus, an increased appar­
ent volume of the central compartment (Vc) could be 
expected, probably because of a slower elimination of the 
compounds by poorly perfused organs of elimination. It 
has long been suggested that distribution of drugs may be 
not only affected by blood flow but also by active transport 
across the endothelium.27 It was postulated that the 
binding affinity of the chiral forms of ketamine to mem­
brane receptors responsible for protein-mediated transport 
across the vascular endothelium might exhibit stereospeci­
ficity, showing different distribution profiles between enan­
tiomers. However, several authors failed to demonstrate 
ketamine distribution to be stereoselective in humans10 11 28 
and in dogs.18 Similarly, in the present study, the half-lives 
and the Vc for the ketamine enantiomers did not differ 
significantly between and within groups, suggesting that 
ketamine distribution is not enantio selective in the equine 
species either.
MRT and C1B values calculated from the arterial plasma 
ketamine concentrations determined after S-ketamine or 
R-/S-ketamine i.v. administration were similar for all 
enantiomers. Studies conducted in humans showed a 
significantly higher C1B for S-ketamine compared with 
R-ketamine after administration of either enantiomer. " " 
Ihmsen and colleagues10 showed a higher S-ketamine body 
clearance in men when the drug was administered as an 
infusion of the pure enantiomer compared with an infusion 
of the racemate. In contrast, Yanagihara and colleagues30 
showed no differences between the pharmacokinetics of 
ketamine enantiomers and this dissimilarity was attributed to 
variability related to human races. Inter-individual variations 
between comparison groups, differences in the sampling site 
(arterial vs venous), or both might also account for such 
discrepancies.10
Several factors seem to have an important impact on the 
metabolism of the ketamine isoforms. Ketamine is rapidly 
and extensively metabolized by the hepatic microsomal 
cytochrome P450 enzymes to norketamine, hydroxynorke­
tamine, hydroxyketamine, and dehydronorketamine.31 35 
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In vitro studies revealed that A'-dcrncthylation of 
S-ketamine by human liver microsomes is 20% larger than 
that of R-ketamine and 10% greater when compared with 
the racemic compound.36 Two enzymes with stereospecific 
preference for one enantiomer over the other, or four 
enzymes with different stereospecific substrate activities 
and different metabolic rates might account for this 
enantioselective A'-dcrncthylation.36 In contrast another 
in vitro study with human liver microsomes suggested 
a non-enantioselective A'-dcrncthylation of R- and 
S-ketamine.37
The comparable values obtained for the calculated phar­
macokinetic variables of the S-isoforms of ketamine and 
norketamine in both groups suggest no interference of the 
R-enantiomer with the overall elimination of the 
S-enantiomer in the racemate. However, the significant 
differences found for the R- and S-norketamine in the 
RS-k treatment group suggest that some differences exist 
with regard to their particular metabolic pathways. This 
finding corresponds with data in which similar results 
were obtained after a single dose of S- or R-/S-ketamine 
administration to human patients11 and horses.5 In the 
latter study, a S/R ratio for norketamine of 75:25 immedi­
ately after and 90:10 40 min after i.v. administration of 
R-/S-ketamine (6 mg kg-1) was reported. The authors 
postulated that these ratios could be the consequence of 
substrate enantioselectivity of the cytochrome-dependent 
A'-dcrncthylation. In the present study, an enzyme- 
substrate competition seems unlikely because similar C1B 
rates were found for the S-enantiomer in both groups 
suggesting the presence of other enantioselective processes 
involved in the elimination of ketamine. Norketamine is a 
pharmacologically active metabolite and was found to 
have a potency of around 30% of that of the parent drug.38 
The hydroxylated metabolite 6-hydroxynorketamine has 
been reported to be a weaker anaesthetic and to produce 
less post-anaesthetic excitation than norketamine.39 
Consequently, norketamine elimination pathways might 
have a relevant influence on the overall ketamine activity. 
Interestingly, the hydroxylation of norketamine also 
exhibited enantioselectivity at different positions on the 
cyclohexanone ring.35 Therefore, it could be possible that 
in the present study, R-norketamine hydroxylation may 
have prevailed, accounting for the lower plasma concen­
trations reflected into the lower AUC and Cmax observed 
for that metabolite. Unfortunately, we were unable to 
quantify the plasma concentrations of the hydroxylated 
forms of norketamine to test this hypothesis.
Renal excretion seems to play a significant role in nor­
ketamine elimination in horses.40 Differences in plasma 
protein binding leading to different renal clearance may be 
expected for chiral compounds.41 Therefore, different renal 
clearance rates for norketamine enantiomers could also 
explain the higher concentrations obtained for 
S-norketamine in ponies' plasma when compared with 
those of R-norketamine. Kaka and colleagues4 proposed 
involvement of extrahepatic pathways in the ketamine 
metabolism in horses because the ketamine C1B exceeded 
the calculated hepatic plasma flow rate. Studies performed 
in rats reported extrahepatic inversion of R to S-ketamine 
with subsequent metabolism to S-norketamine.42 In the 
present study, no R-ketamine was detected after adminis­
tration of the pure S-enantiomer, and after administration 
of the racemate, the mean plasma concentrations of R- and 
S-ketamine were similar, suggesting no inversion between 
the R- and S-enantiomers. Geisslinger and colleagues11 
proposed that a possible inversion from R- to S-ketamine 
could be masked by different stereoselective C1B rates, 
resulting also in similar concentration profiles for both 
enantiomers. However, the C1B of the R- and S-ketamine 
were similar in our study.
Although the study reported here was mainly designed 
to evaluate the pharmacokinetics of ketamine and norketa­
mine enantiomers, some cardiopulmonary data were also 
collected. Generally, low doses of R-/S-ketamine are 
known to increase heart rate and MAP as a consequence 
of direct sympathetic stimulation.43 The reduction in MAP 
observed for both compounds in the first 10 min after drug 
administration could have been the result of direct central 
nervous system depression in response to the high doses 
used here. S-ketamine seemed to have produced a stronger 
cardiac stimulation as evaluated by higher PR values 
observed for the S-k group compared with the RS-k group. 
In vitro studies showed an inhibition of the uptake of nor­
adrenaline at adrenergic neuronal endings by ketamine, 
which occurred pre-synaptically with both enantiomers but 
also post-synaptically with the S-isoform.44 On the other 
hand, overall mean MAP values remained significantly 
lower over time in the S-k treatment group compared with 
the racemate. The reduced MAP values observed in the 
S-k treatment group could have induced an autonomic 
reflex response that increased the heart rate and vice versa 
for the RS-k treatment group. Contrary to these findings, 
Filzek and colleagues45 reported significantly lower heart 
rate and higher MAP values in horses anaesthetized with 
S-ketamine compared with those receiving R-/S-ketamine. 
In man, several studies compared R-/S-ketamine with 
S-ketamine and found equivalent cardiovascular stimula­
tion.104647 Immediately after test drug administration and 
for about 10 min, respiratory depression occurred (apnoea, 
decreases in Rf, VT, and VE). A progressive increase in VE 
was observed in both groups as test drugs were cleared from 
plasma. Increases in Rf might have accounted for the overall 
increases in the mean VE values observed in the RS-k treat­
ment group since VT remained similar between groups. In 
turn, an overall increase in the arterial partial pressure of 
carbon dioxide, reflected as an increase in the overall mean 
Pecq values in the RS-k treatment group, could have stimu­
lated the respiratory system via chemoreceptor activity result­
ing in the observed increases in VE and Rf. Alternatively, 
increases in physiologic dead space could explain the lower 
Pe'cq values observed in the S-k treatment group.
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In conclusion, the disposition of racemic ketamine in 
ponies anaesthetized with 1 iMAC isoflurane is stereo­
selective, leading to higher plasma concentrations of 
S-norketamine. Several factors seem to influence the 
metabolism of the ketamine isoforms. Further studies are 
required to assess the impact of different dose regimes, 
drug combinations, or both on the overall metabolism of 
the enantiomers of ketamine. Under the conditions 
reported here, administration of S-ketamine produced 
different cardiopulmonary effects than those observed with 
R-/S-ketamine. The underlying mechanisms responsible 
for these differences remain to be elucidated.
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